Flat control of tumor growth with angiogenic inhibition

Cancer represents nowadays one of the most destructive and lethal illnesses of our civilization. In the last decades, clinical cancer research shifted towards molecular targeted therapies which have limited side effects in comparison to conventional chemotherapy and radiation therapy. Antiangiogenic therapy is proved to be one of the most promising cancer treatment methods. This paper concerns on the model-based control of tumor growth under angiogenic inhibition. The tumor growth model is nonlinear, augmented with a linear model representing the pharmacokinetics of the applied inhibitor in tumor treatment. The control strategy is based on feedback linearization and path tracking. The result are compared with other, basically linear control strategies which were previously published by our group.

[1]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2011. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Schättler,et al.  A Synthesis of Optimal Controls for a Model of Tumor Growth under Angiogenic Inhibitors , 2005, Proceedings of the 44th IEEE Conference on Decision and Control.

[3]  L. Kovacs,et al.  Linear state-feedback control synthesis of tumor growth control in antiangiogenic therapy , 2012, 2012 IEEE 10th International Symposium on Applied Machine Intelligence and Informatics (SAMI).

[4]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[5]  H. Verheul,et al.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? , 2009, Angiogenesis.

[6]  L. Kovács,et al.  Modeling and optimal control strategies of diseases with high public health impact , 2011, 2011 15th IEEE International Conference on Intelligent Engineering Systems.

[7]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[8]  A. Floren,et al.  ' " ' " ' " . " ' " " " " " ' " ' " " " " " : ' " 1 , 2001 .

[9]  Lin Yuan,et al.  Celastrus Orbiculatus Extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo , 2012, Chinese Journal of Integrative Medicine.

[10]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[11]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[12]  Levente Kovács,et al.  Model-based analysis and synthesis of tumor growth under angiogenic inhibition: A case study , 2011 .

[13]  J M Pluda,et al.  Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. , 1997, Seminars in oncology.

[14]  V. Steele,et al.  Mechanistic considerations in chemopreventive drug development , 1994, Journal of cellular biochemistry. Supplement.

[15]  A. Isidori.  Nonlinear Control Systems , 1985 .